Skip to content
All Podcasts – Lifestyle
Author:
Mylan Inc.
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
May 18, 2026
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
May 7, 2026
Viatris Reports First-Quarter 2026 Financial Results
May 7, 2026
Viatris Announces Quarterly Dividend
May 5, 2026
Viatris Announces Chief Financial Officer Transition
May 4, 2026
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026
April 13, 2026
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
April 10, 2026
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
March 23, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
March 19, 2026
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
March 5, 2026
1
2
Next Page
→